Overview
This case-based program, chaired by Saurabh Malhotra, MD, MPH, is designed to educate imaging physicians and technologists on the latest acquisition, interpretation, and reporting techniques of technetium-99m hydroxy methylene diphosphonate (Tc-99m HMDP) and technetium-99m pyrophosphate (Tc-99m PYP) and provide best practices for the use of each tracer.
Ongoing supply chain disruptions have made it challenging to rely on Tc-99m PYP for diagnosing transthyretin cardiomyopathy (ATTR-CM)—potentially delaying critical treatment for your patients. Tc-99m HMDP is a viable alternative, but how does it compare to Tc-99m PYP? Join this webinar to learn the key differences in acquisition, interpretation, and reporting.
Claim your Certificate and Credit
To claim your CME certificate, you must first complete a post-test and evaluation. To do this, click the “Get Started” or “Login” button. Please note, the button you see is dependent if you are currently logged in. Upon clicking this button, follow the cues to move through the post-test and evaluation to receive your certificate.
Target Audience
The program is intended for nuclear cardiologists, multimodality imaging cardiologists, imaging technologists, cardiologists/interventionalists and others interested in understanding best practices in use of Tc-99m HMDP and Tc-99m PYP in ATTR-CM diagnosis.
Overall Goals
Goals of this program include:
✔ Identifying best practices for using Tc-99m HMDP and Tc-99m PYP in ATTR-CM diagnosis.
✔ Discussing key similarities and differences between Tc-99m PYP and Tc-99m HMDP.
✔ Reviewing the importance of SPECT and SPECT/CT imaging in diagnosing ATTR-CM.
✔ Demonstrating real-world case studies to enhance your clinical decision-making.
Learner Objectives
By the end of the program, you should be able to:
- Outline the similarities and differences between Tc-99m HMDP and Tc-99m PYP in acquiring, interpreting and reporting study results for ATTR-CM.
- Describe optimized cardiac amyloid radionuclide scintigraphy protocols to ensure accurate diagnosis with Tc-99m PYP and Tc-99m HMDP.
- Identify imaging characteristics that impact interpretation and diagnostic accuracy.
- Specify key components of an appropriate report to enhance diagnostic precision.
Statement of Need
Over the past several years, supply chain interruptions have resulted in shortages of the kit for preparation of Tc-99m PYP, limiting the use of this tracer for detection of ATTR-CM in many cardiology practices and potentially delaying treatment. Tc-99m HMDP has not been widely used to diagnose ATTR-CM, but literature indicates it is a reasonable alternative to Tc-99m PYP. However, similarities and differences exist.
Accreditation and Continuing Education Credit
Evaluation Deadline:
AMA PRA Category 1 Credits™- December 31, 2025. The American Society of Nuclear Cardiology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians: The American Society of Nuclear Cardiology designates this internet live activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure Policy and Disclosures
As an accredited provider of the Accreditation Council for Continuing Medical Education (ACCME), The American Society of Nuclear Cardiology (ASNC) adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. In compliance with these standards, it is ASNC’s policy to ensure balance, independence, objectivity, and scientific merit in all of its educational activities through the disclosure of all financial relationships with ineligible companies and mitigation of conflicts of interest. The financial interest or relationships requiring disclosure are outlined in ASNC’s CME Conflict of Interest Policy. All persons who influenced the content of this activity are required to disclose all financial relationships. The American Society of Nuclear Cardiology has reviewed these disclosures and mitigated or managed all identified conflicts of interest through a peer review process.
The following planners, presenters, peer reviewers, and staff reported no financial relationships:
Firas Al Badarin, MD
Linda Giering, PhD (ASNC staff)
Wendy Passerell (ASNC staff)
The following planners, presenters, peer reviewers, staff reported financial relationships:
Cigdem Akincioglu, MD: Research grant and Speaker Honoraria - Pfizer
Wael Jaber, MD: Consultant – Boston Scientific, Pfizer
Saurabh Malhotra, MD, MPH: Speaker’s bureau – Pfizer, Alnylam; AstraZeneca; Consultant – Viz.ai; Advisory Board – Pfizer, Alnylam
Prem Soman, MD, PhD: Research grant – Pfizer; Consultant – Alnylam, Spectrum Dynamics, Eidos, Pfizer
Continuing Education Term of Approval
Release Date: March 18, 2025
Expiration Date: December 31, 2025
After December 31, 2025, a fee will be charged to obtain your certificate.
Method of Participation
This activity is a webinar that took place on March 18, 2025. Online content available to learners includes the recorded lecture. A Post-Test and Evaluation must be completed in order to claim credit for this activity.
Commercial Support
This program is supported by an unrestricted educational grant from Pfizer, Inc.
Contact Information
American Society of Nuclear Cardiology
10300 Eaton Place, Suite 301
Fairfax, VA 22030
703-459-2555 | info@asnc.org | www.ASNC.org